Send to

Choose Destination
Diabetes Res Clin Pract. 2014 Nov;106(2):383-9. doi: 10.1016/j.diabres.2014.07.025. Epub 2014 Jul 27.

The DEXLIFE study methods: identifying novel candidate biomarkers that predict progression to type 2 diabetes in high risk individuals.

Author information

Steno Diabetes Center, Gentofte, Denmark.
Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
Cancer Epigenetics and Biology Program, Spanish Biomedical Research Centre Network for Epidemiology and Public Health, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, Barcelona, Spain.
Institute for Research in Biomedicine, Barcelona, Spain; Departament de Bioquímica I Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Spain.
Voluntary Health Insurance Board, Dublin, Ireland.
University of Newcastle-on-Tyne, Newcastle, UK.
Metabolon Inc., Durham, NC, USA.
Pintail Ltd., Blackrock, Co., Dublin, Ireland.
Centre for Preventive Medicine, School of Health and Human Performance, Dublin City University, Dublin, Ireland.
Steno Diabetes Center, Gentofte, Denmark. Electronic address:


The incidence of type 2 diabetes (T2D) is rapidly increasing worldwide and T2D is likely to affect 592 million people in 2035 if the current rate of progression is continued. Today, patients are diagnosed with T2D based on elevated blood glucose, either directly or indirectly (HbA1c). However, the information on disease progression is limited. Therefore, there is a need to identify novel early markers of glucose intolerance that reflect the underlying biology and the overall physiological, metabolic and clinical characteristics of progression towards diabetes. In the DEXLIFE study, several clinical cohorts provide the basis for a series of clinical, physiological and mechanistic investigations in combination with a range of--omic technologies to construct a detailed metabolic profile of high-risk individuals across multiple cohorts. In addition, an exercise and dietary intervention study is conducted, that will assess the impact on both plasma biomarkers and specific functional tissue-based markers. The DEXLIFE study will provide novel diagnostic and predictive biomarkers which may not only effectively detect the progression towards diabetes in high risk individuals but also predict responsiveness to lifestyle interventions known to be effective in the prevention of diabetes.


Biomarkers; Lifestyle intervention; Prevention; Type 2 diabetes

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center